

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Single Technology Appraisal**

**Nivolumab with ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]**

**Final Stakeholder list**

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Bristol Myers and Squibb (nivolumab and ipilimumab)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Black Health Agency for Equality</li> <li>• Bladder and Bowel Community</li> <li>• Bladder and Bowel UK</li> <li>• Bowel Cancer UK</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Cancer52</li> <li>• Childhood Cancer Parents Alliance</li> <li>• Children with Cancer</li> <li>• Colostomy UK</li> <li>• Contact</li> <li>• Helen Rollason Cancer Charity</li> <li>• IA: Ileostomy and Internal Pouch Association</li> <li>• Independent Cancer Patients Voice</li> <li>• Macmillan Cancer Support</li> <li>• Maggie’s Centres</li> <li>• Marie Curie</li> <li>• Pelican Cancer Foundation</li> <li>• Red Trouser Day</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Teenage Cancer Trust</li> <li>• Young Lives vs Cancer</li> <li>• Tenovus Cancer Care</li> </ul> <p><u>Healthcare Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> <li>• Association of Coloproctology of Great Britain and Ireland</li> <li>• British Geriatrics Society</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Confederation</li> <li>• Promega</li> <li>• Scottish Medicines Consortium</li> <li>• Scottish Society of Gastroenterology</li> <li>• Welsh Government</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Amgen (panitumumab)</li> <li>• Dr Reddy’s Laboratories (capecitabine)</li> <li>• Glenmark Pharmaceuticals (capecitabine)</li> <li>• Medac (folinic acid, fluorouracil, irinotecan, oxaliplatin)</li> <li>• Merck (cetuximab)</li> <li>• MSD (pembrolizumab)</li> <li>• Pfizer (irinotecan)</li> <li>• Ranbaxy (irinotecan, oxaliplatin)</li> <li>• Seacross Pharmaceuticals (irinotecan, oxaliplatin)</li> </ul>

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• British Institute for Radiology</li> <li>• British Oncology Pharmacy Association</li> <li>• British Psychosocial Oncology Society</li> <li>• British Society of Gastroenterology</li> <li>• British Society of Paediatric Gastroenterology, Hepatology and Nutrition</li> <li>• Cancer Research UK</li> <li>• Children's Cancer &amp; Leukaemia Group</li> <li>• Neonatal and Paediatric Pharmacists Group</li> <li>• Primary Care Society for Gastroenterology</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Radiologists</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society and College of Radiographers</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> </ul>	<p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Bowel Research UK</li> <li>• Cochrane Colorectal Group</li> <li>• Genomics England</li> <li>• Institute of Cancer Research</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

**Definitions:**

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG)..

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.